EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐world genomic landscape of colon and rectal cancer

Markus Schulze, XiaoZhe Wang, Jawad Hamad, Julia C F Quintanilha iD, Lincoln W Pasquina iD, Julia F Hopkins, Juergen Scheuenpflug, Zheng Feng iD

FEBS Open Bio · 2025

DOI: 10.1002/2211-5463.13957 ↗

Kurz gefasst

Fachartikel in der Zeitschrift FEBS Open Bio, 2025. Verfasst von Markus Schulze und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Measurement Sciences, Global Research & Development, Merck KGaA, Darmstadt, Germany. Hauptthemen laut MEDLINE: Rectal Neoplasms, Colonic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Healthcare KGaA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

MAPK signaling activation is an important driver event in colorectal cancer (CRC) tumorigenesis that informs therapy selection, but detection by liquid biopsy can be challenging. We analyze real‐world comprehensive genomic profiling (CGP) data to explore the landscape of alterations in BRAF or RAS in CRC patients ( N = 51 982) and co‐occurrence with other biomarkers. A pathogenic RAS or BRAF alteration was found in 63.2% and 57.9% of colon and rectal cancer samples, respectively. In a subset of 140 patients with both tissue‐ and liquid‐based CGP, the sensitivity of liquid for results found by tissue was 100% when ctDNA tumor fraction was at least 1%, illustrating the utility of tissue and liquid biopsy in detecting driver alterations in CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rectal NeoplasmsColonic NeoplasmsHumansProto-Oncogene Proteins B-rafGenomicsBiomarkers, TumorMutationMaleFemaleLiquid BiopsyCirculating Tumor DNA

Stichwörter der Autor:innen

BRAFRAScolorectal cancerreal‐world data

Substanzen

Proto-Oncogene Proteins B-rafBRAF protein, humanBiomarkers, TumorCirculating Tumor DNA

Autor:innen und Institutionen

  • Clinical Measurement Sciences, Global Research & Development, Merck KGaA, Darmstadt, Germany.
  • Clinical Measurement Sciences, Global Research & Development, EMD Serono, Billerica, MA, USA.
  • Medical Unit Oncology, Merck Healthcare KGaA, Darmstadt, Germany.
  • Foundation Medicine Inc, Cambridge, MA, USA.

ORCID-Profile: Julia C F Quintanilha, Lincoln W Pasquina, Zheng Feng

Förderung

  • Merck Healthcare KGaA

Zitieren

APA

Schulze, M., Wang, X., Hamad, J., Quintanilha, J. C. F., Pasquina, L. W., Hopkins, J. F., Scheuenpflug, J., & Feng, Z. (2025). Real‐world genomic landscape of colon and rectal cancer. FEBS Open Bio. https://doi.org/10.1002/2211-5463.13957

Vancouver

Schulze M, Wang X, Hamad J, Quintanilha JCF, Pasquina LW, Hopkins JF, et al. Real‐world genomic landscape of colon and rectal cancer. FEBS Open Bio. 2025. doi:10.1002/2211-5463.13957

BibTeX
@article{Schulze2025,
  author = {Schulze, Markus and Wang, XiaoZhe and Hamad, Jawad and Quintanilha, Julia C F and Pasquina, Lincoln W and Hopkins, Julia F and Scheuenpflug, Juergen and Feng, Zheng},
  title = {Real‐world genomic landscape of colon and rectal cancer},
  journal = {FEBS Open Bio},
  year = {2025},
  doi = {10.1002/2211-5463.13957}
}
Kostenlos starten →